6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-(methylamino)pyridine-3-carbonitrile | 852315-01-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-(methylamino)pyridine-3-carbonitrile
• 英文别名: 5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-2-(methylamino)pyridine-3-carbonitrile
• CAS: 852315-01-6
• 化学式: C₁₉H₁₂Cl₃N₃
• 分子量: 388.683
• InChiKey: MOMXWVZGDHGETO-UHFFFAOYSA-N

物化性质

• 沸点：
  499.0±45.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  48.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-(methylamino)pyridine-3-carbonitrile 、 alkaline earth salt of/the/ methylsulfuric acid 在 甲基溴化镁 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 3-acetyl-4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-1,8-naphthyridin-2(1H)-one
  参考文献：
  名称：

  功能化的1,8-萘啶酮的合成及其作为新型口服活性CB1受体反向激动剂的评估。

  摘要：

  合成，SAR和绑定亲和性描述了新型的1,8-萘啶酮CB1受体特异性反向激动剂。食物摄入，基因敲除小鼠和14的药代动力学评估表明，该化合物是CB1的有效口服活性调节剂。

  DOI：

  10.1016/j.bmcl.2005.10.028
• 作为产物：
  描述：

  2-chloro-6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyridine-3-carbonitrile 、 甲胺 以 四氢呋喃 为溶剂， 生成 6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-(methylamino)pyridine-3-carbonitrile
  参考文献：
  名称：

  功能化的1,8-萘啶酮的合成及其作为新型口服活性CB1受体反向激动剂的评估。

  摘要：

  合成，SAR和绑定亲和性描述了新型的1,8-萘啶酮CB1受体特异性反向激动剂。食物摄入，基因敲除小鼠和14的药代动力学评估表明，该化合物是CB1的有效口服活性调节剂。

  DOI：

  10.1016/j.bmcl.2005.10.028

文献信息

• [EN] SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES<br/>[FR] DERIVES DE NAPHTYRIDINONE SUBSTITUES
  申请人：MERCK & CO INC

  公开号：WO2005047285A1

  公开（公告）日：2005-05-26

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或逆向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可作为中枢作用药物用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化症和吉兰-巴雷综合征）、病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖或进食障碍的治疗，以及治疗哮喘、便秘、慢性肠道假性梗阻和肝硬化。
• Substituted naphthyridinone derivatives
  申请人：Debenham S. John

  公开号：US20070032517A1

  公开（公告）日：2007-02-08

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作中枢作用药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化症和格林-巴利综合症）以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。该化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。
• Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: Synthesis, SAR and biological evaluation
  作者：Christina B. Madsen-Duggan、John S. Debenham、Thomas F. Walsh、Lin Yan、Pei Huo、Junying Wang、Xinchun Tong、Julie Lao、Tung M. Fong、Jing Chen Xiao、Cathy R.-R.C. Huang、Chun-Pyn Shen、D.Sloan Stribling、Lauren P. Shearman、Alison M. Strack、Mark T. Goulet、Jeffrey J. Hale

  DOI：10.1016/j.bmcl.2010.04.071

  日期：2010.6

  Synthesis and structure-activity relationships of cannabinoid-1 receptor (CB1R) inverse agonists based on dihydro-pyrano[2,3-b] pyridine and tetrahydro-1,8-naphtyridine scaffolds are presented. Rat food intake and pharmacokinetic evaluation of 13g, 13i, 13k and 17a revealed these compounds to be highly efficacious orally active modulators of CB1R. (C) 2010 Elsevier Ltd. All rights reserved. NH
• EP1682550A4
  申请人：——

  公开号：EP1682550A4

  公开（公告）日：2007-01-03
• SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES
  申请人：Merck & Co., Inc.

  公开号：EP1682550A1

  公开（公告）日：2006-07-26